Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Terapeutiske vacciner er et nyt behandlingsprincip ved kastrationsresistent prostatacancer

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Telemedicin til monitorering af inflammatoriske tarmsygdomme og colon irritabile

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Amyloid transthyretinkardiomyopati

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Rygning i graviditeten

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Androgent insensitivitetssyndrom opdaget pga. diskordans mellem prænatale vurderinger af fosterkøn.

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Behandling af tymom og thymuskarcinom

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Elevated miR-615-3p Expression Predicts Adverse Clinical Outcome and Promotes Proliferation and Migration of Prostate Cancer Cells

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Palliative Prostate Artery Embolization for Prostate Cancer: A Case Series

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Predictive value of AZGP1 following radical prostatectomy for prostate cancer: a cohort study and meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Community-based football in men with prostate cancer: 1-year follow-up on a pragmatic, multicentre randomised controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Castration-resistant prostate cancer (CRPC) is defined as tumour progression despite castrate levels of serum testosterone. During the past decade a number of new therapies, including chemotherapy and novel endocrine agents have been approved for CRPC treatment. The continued need for new effective drugs in CRPC has led to development of a novel therapeutic approach in CRPC treatment. Therapeutic vaccines activate the immune system to kill prostate cancer cells. This review describes recent pivotal phase 2 and 3 trials of CRPC vaccines and discusses the impact on future CRPC management.

Translated title of the contributionTherapeutic vaccines is a novel approach in castration-resistant prostate cancer treatment
Original languageDanish
JournalUgeskrift for Laeger
Volume177
Issue number20
Pages (from-to)V11140628
ISSN0041-5782
Publication statusPublished - 11 May 2015

ID: 45343797